^
    Back
    Association details:
    Biomarker:PD-1 expression
    Cancer:Renal Cell Carcinoma
    Drug:Loqtorzi (toripalimab-tpzi) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Safety, Efficacy and Biomarker Analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial

    Published date:
    04/24/2020
    Excerpt:
    This phase II study was to evaluate safety and efficacy of toripalimab in advanced Chinese melanoma patients who had failed in systemic treatments....Patients with positive PD-L1 staining in tumor biopsies had significant better ORR (38.5% versus 11.9%, p=0.0065), PFS (7.7m versus 2.7m, p=0.013) and OS (not reached versus 14.4m, p=0.0005) than PD-L1 negative patients.
    DOI:
    10.1158/1078-0432.CCR-19-3922